Zhejiang Yongning Pharmaceutical Co.,Ltd is one of the ten top valuable enterprises for investment in China Pharmaceutical Industry in 2012.It is also the first pharmaceutical company which makes products from Cephalosprin side chain to APIs and then to finish products.It's previous name was Zhejiang Yongning Pharmaceutical Factory which was established in 1974 and was a state-owned factory.It was reformed into private joint-stock company in 2006.
Company's total assets are 800 million yuan and it takes up an area of 180,000 square meters.The number of staffs are more than 1200 including more than 300 engineers and technicians.The products have five classes of chemical & pharmaceutical intermediates, APIs and their preparations, Chinese medicines,health products including more than one hundred varieties and specifications.
Our company has 6 kinds of independent intellectual property,2 copies of brand certificates of National Traditional Chinese Medicines Pretected and 10 pieces of invention patent,such as Cefotiam HCl crude & Cefotiam HCl in China; Beta-Lactamase-Resistant Cephalosporin Ester Compounds and Salts of Thereof in U.S.A.,Italy,Spain,Korea and Japan .We also can develop the new specification and new items according to our customers' specific requirements. We have already developed several new specification & new items according to some very famous pharmaceutical factories fromU.K.,Italy,Switzerland,KoreaandJapan.
Our products have been sold well in the whole country and have also been exported to Asia,America and Europe, such as Japan,Korea,India, Pakistan,Egypt,Switzerland,Italy,Ukraine,Mexico,Brasil etc with good quality and competitive price.In the meantime,our products have won a high reputation in different markets.
One of the best 50 companies inChina’s Pharmaceutical Industry.
The national member unit of 863 Program.
The national key new high-tech enterprise of Torch Program
The largest management and the best economic benefits enterprise in Zhejiang province.
Having independent import and export right
Having more than 60 kinds of new medicines,6 products with independent intellectual property rights
